Iovance Biotherapeutics
IOVA
IOVA
236 hedge funds and large institutions have $1.71B invested in Iovance Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 101 increasing their positions, 70 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
5% less funds holding
Funds holding: 248 → 236 (-12)
18% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 50
34% less capital invested
Capital invested by funds: $2.6B → $1.71B (-$888M)
Holders
236
Holding in Top 10
4
Calls
$32.1M
Puts
$18.1M
Top Buyers
| 1 | +$54.4M | |
| 2 | +$45.7M | |
| 3 | +$26.3M | |
| 4 |
D.E. Shaw & Co
New York
|
+$21.6M |
| 5 |
Goldman Sachs
New York
|
+$15.2M |
Top Sellers
| 1 | -$110M | |
| 2 | -$51.3M | |
| 3 | -$33.1M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$16.6M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$15.1M |